Alpha 2.0
Login Register
» Articles » PMID: 31644849

PARAGON-HF - Why We Do Randomized, Controlled Clinical Trials

Overview
Journal N Engl J Med
Specialty General Medicine
Date 2019 Oct 24
PMID 31644849
Citations 5
Authors
Christopher M OConnor
Christopher deFilippi
Affiliations
Soon will be listed here.
Citing Articles

Synthetic growth hormone-releasing hormone agonist ameliorates the myocardial pathophysiology characteristic of heart failure with preserved ejection fraction.

Dulce R, Kanashiro-Takeuchi R, Takeuchi L, Salerno A, Wanschel A, Kulandavelu S Cardiovasc Res. 2022; 118(18):3586-3601.

PMID: 35704032 PMC: 10202441. DOI: 10.1093/cvr/cvac098.

Women and Diabetes: Preventing Heart Disease in a New Era of Therapies.

Galati G, Sabouret P, Germanova O, Bhatt D Eur Cardiol. 2021; 16:e40.

PMID: 34777580 PMC: 8576483. DOI: 10.15420/ecr.2021.22.

Could a Multi-Marker and Machine Learning Approach Help Stratify Patients with Heart Failure?.

Lotierzo M, Bruno R, Finan-Marchi A, Huet F, Kalmanovich E, Rodrigues G Medicina (Kaunas). 2021; 57(10).

PMID: 34684033 PMC: 8538712. DOI: 10.3390/medicina57100996.

Circulating Neprilysin Level Predicts the Risk of Cardiovascular Events in Hemodialysis Patients.

Hwang H, Kim J, Kim Y, Lee Y, Lee D, Ahn S Front Cardiovasc Med. 2021; 8:684297.

PMID: 34212014 PMC: 8239158. DOI: 10.3389/fcvm.2021.684297.

Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence.

Choi H, Shin M Korean J Intern Med. 2020; 35(3):498-513.

PMID: 32392658 PMC: 7214374. DOI: 10.3904/kjim.2020.105.